The aim of the study was: 1) to perform an exploratory analysis using the DMETTM chip to find new treatment predictive markers in a subset of the cohort and 2) to examine these potential markers with a special focus on CYP19A1 in relation to a risk for early events in the extended cohort of AI-treated breast cancer patients. This evidence concerns the gene CYP19A1 and breast carcinoma.